FakhraVac (Catalan Wikipedia)

Analysis of information sources in references of the Wikipedia article "FakhraVac" in Catalan language version.

refsWebsite

Global rank Catalan rank

5web.archive.org

1^st place

1^st place

low place

low place

2tasnimnews.com

995^th place

low place

268^th place

744^th place

low place

low place

low place

low place

aljazeera.com

«Iran starts human trials of its third domestic COVID vaccine». Al Jazeera, 16-03-2021.

inss.org.il

The Assassination of Fakhrizadeh: Considerations and Consequences

irct.ir

en.irct.ir

«Phase 1, safety, immunogenicity and dose finding for two strengths of 0.5 × 10^6 and 2.5 × 10^6 (TCID50) inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) injected in two schedules of two doses, 2 and 3 weeks apart in healthy adults aged 18-55 years: a randomized, double blind, placebo controlled, clinical trial». en.irct.ir. Iran Registry of Clinical Trials. Arxivat de l'original el 28 d’abril 2021. [Consulta: 21 març 2021].
«Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial». en.irct.ir. Iran Registry of Clinical Trials. Arxivat de l'original el 16 de juny 2021. [Consulta: 15 juny 2021].
«IRCT | Comparison of the safety, efficacy and immunogenicity of Fakhravac and Sinopharm SARS-CoV-2 vaccines, in adults aged 18 and over; a phase III randomised, non-inferiority clinical trial». en.irct.ir. Arxivat de l'original el 2021-09-07. [Consulta: 7 setembre 2021].

parstoday.com

«Research center run by Fakhrizadeh produced first COVID-19 test kits for Iranians: Defense minister». Pars Today, 28-11-2020. Arxivat de l'original el 5 December 2020. [Consulta: 7 setembre 2021].

tasnimnews.com

«Iran Authorizes Emergency Use of Third Homegrown Vaccine - Defense news» (en anglès). Tasnim News Agency. [Consulta: 9 setembre 2021].
«Iran Authorizes Emergency Use of Third Homegrown Vaccine - Defense news» (en anglès), 09-09-2021. Arxivat de l'original el 2021-09-09. [Consulta: 9 setembre 2021].

web.archive.org

«Phase 1, safety, immunogenicity and dose finding for two strengths of 0.5 × 10^6 and 2.5 × 10^6 (TCID50) inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) injected in two schedules of two doses, 2 and 3 weeks apart in healthy adults aged 18-55 years: a randomized, double blind, placebo controlled, clinical trial». en.irct.ir. Iran Registry of Clinical Trials. Arxivat de l'original el 28 d’abril 2021. [Consulta: 21 març 2021].
«Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial». en.irct.ir. Iran Registry of Clinical Trials. Arxivat de l'original el 16 de juny 2021. [Consulta: 15 juny 2021].
«IRCT | Comparison of the safety, efficacy and immunogenicity of Fakhravac and Sinopharm SARS-CoV-2 vaccines, in adults aged 18 and over; a phase III randomised, non-inferiority clinical trial». en.irct.ir. Arxivat de l'original el 2021-09-07. [Consulta: 7 setembre 2021].
«Research center run by Fakhrizadeh produced first COVID-19 test kits for Iranians: Defense minister». Pars Today, 28-11-2020. Arxivat de l'original el 5 December 2020. [Consulta: 7 setembre 2021].
«Iran Authorizes Emergency Use of Third Homegrown Vaccine - Defense news» (en anglès), 09-09-2021. Arxivat de l'original el 2021-09-09. [Consulta: 9 setembre 2021].